LY-4 inhibited melanoma progression (Fig 5D, S4E Fig) and this outcome was accompanied by reduced eIF2α phosphorylation and CHOP accumulation suggesting on-target effects of this drug (Fig 5E). This evidence concerns the gene DDIT3 and melanoma.